drugset
drugset / Trial / NCT04190654

Single-dose Study to Investigate the Plasma PK of KW-6356 and Its Major Metabolite

NCT04190654 ↗

Phase 1 Completed 26 enrolled Kyowa Kirin, Inc.
Non-randomizedParallel-groupOpen-labelOther

Summary

This is an open-label, non-randomized, single-dose study to investigate the plasma PK of KW-6356 and its major metabolite, after a single oral dose of KW-6356, in subjects with mild or moderate hepatic impairment and in healthy adults

Timeline

Start
2019-11-26
Primary completion
2020-03-20
Completion
2020-03-20

Drugs

EvaluationDrugModalityDoseRoute
Subject SIPAGLADENANT Small molecule — Oral

Indications

No indication recorded.